Does Pharmacological Profiling of a New Drug in Normotensive Volunteers Provide a Useful Guideline to Antihypertensive Therapy?

HANS R. BRUNNER, M.D., BERNARD WAEBER, M.D., AND JÜRG NUSSBERGER, M.D.

SUMMARY Similar pressor mechanisms should be active in hypertensive and normotensive subjects since hypertension is a quantitative rather than qualitative disorder. Consequently, if an antihypertensive drug is designed to specifically block a well-defined mechanism involved in blood pressure regulation, it should be possible to evaluate its efficacy rather precisely in normotensive volunteers before even administering the compound to a hypertensive patient. That this is indeed the case is illustrated by the example of angiotensin-converting-enzyme inhibitors. The magnitude of blockade that can be obtained in humans, the minimal dose needed for maximal efficacy, and the onset and duration of action of the agents have all been precisely determined in normotensive volunteers. Subsequent administration to hypertensive patients merely confirmed these findings. Moreover, if the antihypertensive effect of converting-enzyme inhibitors could not be predicted in an individual hypertensive patient, this is not related to some unknown action of the drug that cannot be assessed in normal volunteers but rather to our lack of understanding of the precise mixture of pathogenetic mechanisms prevailing in any particular patient. Only the safety evaluation and the search for side-effects still has to be carried out in nonspecific fashion, thus requiring long-term observations in large numbers of patients. If the tolerance of new converting-enzyme inhibitors were more predictable, the number of studies in hypertensive patients could be drastically reduced since the antihypertensive profile of any new converting-enzyme inhibitor can probably be precisely determined in normotensive volunteers. (Hypertension 5 (supp III): III-101-III-107, 1983)

KEY WORDS • hypertension • antihypertensive therapy • angiotensin converting-enzyme inhibition • captopril • anopril

TRADITIONALLY, drugs used to treat various diseases have been developed empirically through vast screening programs. The most spectacular results were often obtained in areas where they were least expected. Mechanisms of action were usually not well understood, and there was also a lack of knowledge of the pathogenetic mechanisms involved in the disease. Except for acute tolerance studies, drug administration in normal volunteers was of limited usefulness for the development of guidelines for the therapeutic use of such compounds. Nevertheless, new drug assay techniques in plasma, urine, and feces made pharmacokinetic studies more widely available. However, considerable discrepancies between such pharmacokinetic observations and therapeutic profiles of some drugs have become apparent.¹

For instance, with diuretics² or propranolol,³ therapeutic efficacy and plasma drug levels have not always been found to be strictly related.

A progressively better understanding of pathogenetic mechanisms involved in various diseases has markedly influenced the development of new therapeutic agents. Thus, in recent years, new drugs have been more and more based on prospective design, with a very specific mechanistic aim in mind rather than on mass screening. As a result, these agents interfere specifically with well-defined mechanisms. This great specificity probably enhances efficacy and may in addition improve the safety profile by avoiding nonspecific side-effects.

As pointed out many years ago by Sir George Pickering, hypertension is a quantitative rather than a qualitative disorder.⁴ The mechanisms involved in the disease, even if all are not yet completely understood, probably also exist in normotensive subjects, albeit in a quantitatively different mixture. Accordingly, if the mechanism of action of an antihypertensive agent is well understood and directed specifically to one factor

From the Division of Nephrology and Hypertension, Centre Hospitalier Universitaire, Lausanne, Switzerland.
Address for reprints: Hans R. Brunner, M.D., Dept of Medicine, C.H.U.V., 1011 Lausanne, Switzerland.
involved in blood pressure regulation, studies of its effect in normotensive volunteers will provide useful information to develop guidelines for the treatment of hypertensive patients.

Agents that inhibit angiotensin-converting enzyme and thereby the generation of angiotensin II (AII) certainly are representatives of this new generation of drugs based on prospective design and directed at well-defined mechanisms. This has become increasingly clear as it now more and more evident that their effect on bradykinin metabolism probably has only a limited influence on blood pressure regulation. These compounds have the additional and specific advantage that methods are available not only to measure plasma levels of the administered drug but also to quantitate the various components of the pressor system on which they exert their effect. In the following analysis, we shall evaluate retrospectively how much information can be gained from the study of converting-enzyme inhibitors in normotensive volunteers that might be useful for the subsequent treatment of hypertensive patients.

Useful Information Obtained from Studies in Normotensive Volunteers

Blockade of the Renin System

In assessing a new drug designed specifically to inhibit the renin angiotensin system by blocking the conversion of angiotensin I (AI) to AII, the first task would seem to be to demonstrate in humans that the drug produces this effect. Several techniques have been used to evaluate this action. The most direct but also most invasive approach is intraarterial pressure intravenous monitoring during bolus injections of AI in normotensive volunteers after administration of the drug. In this way, it was shown for the first time that teprotide or SQ 20,881 blocks the pressor effect of exogenous AI in normal humans. In later studies, this was also demonstrated with the first orally active converting-enzyme inhibitor SQ 14,225 or captopril of MK 421 or MK 521.14 RHC 3569,12 and CGS 13945.13 Of course, this observation in turn provides more strength to the changes in plasma AII levels measured in the same volunteers.

Another way of assessing blockade of converting-enzyme activity is to measure plasma converting-enzyme activity in the normal volunteers before and after administration of a converting enzyme inhibitor. Plasma converting-enzyme activity in normal volunteers was indeed reduced following administration of the converting-enzyme inhibitors studied so far. However, since it is known that in vivo the bulk of conversion of AI to AII does not occur in plasma but rather in the pulmonary capillary bed and possibly in other organs, it could be argued that plasma converting-enzyme activity is not necessarily a good indicator of total angiotensin conversion. That plasma converting-enzyme activity does indeed reflect the total conversion of AI to AII was suggested by findings in normal volunteers receiving MK 421 or MK 521. Figure 2 depicts the relationship between plasma conversion of AI to AII.

Since, in addition to other factors such as potassium, ACTH, and possibly unidentified mechanisms, AII stimulates the secretion of aldosterone from the adrenal cortex, reduction of AII by converting-enzyme inhibitors should result in reduction of plasma aldosterone levels. This expected additional effect has actually been observed following the administration of MK 421,14 MK 521,14 RHC 3459,12 and CGS 13945.13 Of course, this observation in turn provides more strength to the changes in plasma AII levels measured in the same volunteers.
converting-enzyme activity and the systolic blood pressure response to exogenous AI before and after the administration of converting enzyme inhibitors to normal volunteers. It can be seen that the plasma converting enzyme inhibitor activity closely correlates with the systolic BP response to AI, which must be an index of total conversion of AI to Ab.

There is only one precaution that must be observed with the measurement of plasma converting enzyme activity following administration of converting enzyme inhibitors: with captopril and RHC 3569, determinations of converting enzyme activity were not reproducible after storage of the plasma samples, suggesting that some dissociation of the converting enzyme from the antagonist occurs during storage. Accordingly, when using these drugs, samples must be processed immediately. This problem does not exist with MK 421 (enalapril), MK 521, and CGS 13945.

Thus, there exist several methods to assess blockade of converting enzyme inhibition in normal volunteers. The most direct method is blockade of the pressor effect of exogenous AI. Since the alternate methods are well established, one might even argue that this invasive method will not be necessary in the development of any future converting enzyme inhibitors. Once converting enzyme inhibition by a certain agent is established in normal volunteers, this point need not be studied any further in hypertensive patients.

Dose

The minimal dose of the converting enzyme inhibitor needed to obtain nearly complete blockade of the system is also easily established by administering exogenous AI to normal volunteers. In the case of captopril, our initial study carried out in 1976 in 14 normal volunteers clearly established that 20 mg of oral captopril were sufficient to almost completely prevent 320 ng/kg of AI from exerting any major pressor effect. Since converting enzyme inhibitors are designed as competitive antagonists, the dose necessary to obtain consistent blockade of the system should depend on the circulating AI levels, at least in theory. One could therefore argue that the dose established in normal volunteers may not be relevant to hypertensive patients who may exhibit extremely high AI levels. However, the amount of AI administered acutely to the normal volunteers is probably such that comparable plasma levels are rarely if ever reached in hypertensive patients. It is more likely that the minimal dose determined to be necessary to block the pressor effect of exogenous AI in normal volunteers if anything is overestimated rather than underestimated. In the case of captopril, this was suggested by our initial studies in hypertensive patients when we found that an increase in the dose beyond 25 mg p.o. did not enhance the amplitude of the antihypertensive effect (fig. 3). After a prolonged and unfortunate experience with overdosing captopril, which has led to unnecessary side-effects of the medication, well-controlled studies in large numbers of patients have finally confirmed that doses sufficient to block the pressor effect of AI in normal volunteers were identical to those needed to treat hypertensive patients.

A similar observation was made with enalapril where 10 mg was found to be sufficient to block the pressor response to exogenous AI in normal volunteers (fig. 4). While higher doses have been used in hypertensive patients, it appears now that controlled stud-
Mean Arterial Pressure

<table>
<thead>
<tr>
<th>Dose (mg)</th>
<th>Response (mm Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>125 ± 8</td>
</tr>
<tr>
<td>100</td>
<td>121 ± 6</td>
</tr>
<tr>
<td>200</td>
<td>120 ± 8</td>
</tr>
</tbody>
</table>

**Figure 3.** Magnitude and duration of the antihypertensive effect obtained with three different doses of captopril administered on 3 subsequent days. Note that the starting mean blood pressure (MAP) was different each time. Increasing the dose from 25 to 200 mg enhanced the duration but not the magnitude of the antihypertensive effect. (From Brunner et al., see ref. 18.)

The measurement of plasma converting-enzyme activity in normal volunteers is also very useful in establishing the minimal dose of a blocking agent that is necessary to inhibit the renin-angiotensin system. Plasma converting-enzyme activity must be reduced to less than 10% of its initial value to consistently abolish the pressor response to exogenous AI. Therefore, the minimal inhibiting dose should induce a more than 90% inhibition of converting-enzyme activity. In the case of enalapril, this has been shown in normal volunteers to correspond to the 10 mg dose. Moreover, a close correlation between plasma converting-enzyme inhibition and plasma enalapril levels has been demonstrated. Thus, in normal volunteers, it was actually possible to establish the minimal blood concentration of the antagonist that is necessary to inhibit the renin-angiotensin system adequately (fig. 5). Furthermore, by using these minimal doses in normal volunteers, it was also confirmed that they were adequate to induce significant reductions in plasma AI and aldosterone.

**Onset and Duration of Action**

Onset of the action of captopril occurs in less than 15 minutes. This was clearly established in the initial study of 1976, which assessed captopril's effect on the pressor response to exogenous AI in normal volunteers. This rapid onset was confirmed in patients with hypertension or congestive heart failure. In the early volunteer studies with enalapril, a delayed onset of action of close to 2 hours was found, and the initial studies in hypertensive patients immediately confirmed this slower action of this new type of converting-enzyme inhibitor. Measurement of plasma converting-enzyme activity confirmed that 1½ to 2 hours were necessary to obtain a greater than 90% inhibition of plasma enzyme activity following enalapril administration.

Based on the pressor response to exogenous AI in normal volunteers, the action of captopril was found to last for less than 4 hours. In the case of enalapril, this method could not be used in normal volunteers to assess the duration of action for ethical reasons, since we could not leave intraarterial catheters for a long enough period. However, the measurement of plasma converting-enzyme activity demonstrated that inhibition was still excellent 10 hours after drug administration, but after 24 hours, enzyme activity had already reassumed about 20% of its control activity. Not surprisingly then, after 10 hours plasma AI and aldosterone levels were still significantly reduced in these normotensive subjects, but after 24 hours, they were both back to initial values (fig. 6). Again, these observations were confirmed in hypertensive patients following acute administration of enalapril.

Thus, it appears that the minimal doses needed to block the renin system in normal volunteers, as as-
DRUG TESTING IN NORMOTENSIVES/Brunner et al.

Figure 5. Relationship in normal volunteers between the active metabolite (MK 422) of enalapril and the percent inhibition of plasma converting enzyme activity following a single oral dose of 10 mg enalapril. (From Biollaz et al., see ref. 21.)

Figure 6. Time course of plasma angiotensin II and aldosterone following oral administration of 10 mg enalapril (MK 421) or 10 mg MK 521 (LA) to normal volunteers. (From Brunner et al., see ref. 14.)
ing enzyme inhibitors can usually not be predicted at the outset.

In the context of the present discussion, it is however important to recognize that treatment failures with new converting enzyme inhibitors have nothing to do with the drugs per se but are solely related to our lack of understanding of the pathogenetic mechanisms involved in every individual hypertensive patient. If we had a precise knowledge of the contribution of the renin-angiotensin system to the hypertension of each individual patient, it is likely that, based exclusively on the results obtained in normotensive volunteers, the antihypertensive effect of the drug could be precisely predicted in each patient. Our present procedure of evaluating antihypertensive drugs in large numbers of hypertensive patients may, in the case of converting enzyme inhibitors, reveal more about the prevalence of the renin factor in the hypertensive population than any new findings not obtained in normal humans concerning the efficacy of the agent in question.

Duration of Action with Chronic Therapy

Although it was recognized very early that increasing the dose of captopril beyond 25 mg did not enhance the magnitude of the blood pressure reduction in hypertensive patients, most investigators have used considerably higher doses. Knowledge of the drug’s short half-life in normal volunteers prompted a desire to prolong the duration of action by administering large doses. While this has created the well-known problems of side-effects, it has in addition turned out to be totally unnecessary. Thus, even with large doses of captopril given twice daily, converting enzyme could not be blocked around the clock. Nevertheless, blood pressure remained controlled.

Similar observations were made in hypertensive rats treated for long periods of time with captopril; discontinuation of this therapy led only to a slow and gradual increase in blood pressure, clearly in no way related to the half-life of the drug. It is now recognized that chronic treatment with enalapril also lowers blood pressure for a time that exceeds its duration of efficient blockade of the renin-angiotensin system (Merck Sharp and Dohme, unpublished data). One possible explanation is that converting-enzyme inhibitors are less specific than thought hitherto. Possibly some metabolites with nonspecific effects have a much longer half-life. Much more likely is the hypothesis that prolonged treatment of hypertension leads to important adaptive changes including structural modifications in the arterial wall, which reduce the responsiveness of the arterioles to AII and other pressor mechanisms. It is of note that in animals, much smaller doses of AII are needed to achieve a given blood pressure increase if it is administered chronically rather than acutely. Similarly, the intermittent increases in plasma AII occurring with chronic administration of converting enzyme inhibitors do not seem to have the same pressor effect as similarly elevated plasma AII concentrations which are continuously present.

Conclusions

Several methods are available for establishing in normal volunteers the efficacy of converting-enzyme blockade with a considerable degree of precision. In addition, studies in volunteers permit precise determination of the minimal dose needed to obtain close to maximal blockade of the renin system and also the onset and duration of action, at least for acute administration. These findings have subsequently been confirmed in hypertensive patients at least in the case of captopril and enalapril. Studies in hypertensive patients are unlikely to provide any new surprising information, since the unpredictability of an individual hypertensive patient’s response to a converting-enzyme inhibitor is in no way related to some unknown feature of the drug but rather to the absence of a precise knowledge of the pathogenesis of this individual subject. Similarly, the prolonged duration of action of converting-enzyme inhibitors observed in patients treated chronically is more likely related to structural adaptations of the treated organisms than to some unforeseen new effect of the drug.

Thus, now that it is well established how converting enzyme inhibitors act, any new drugs in this class could at least theoretically be largely evaluated in a few normal volunteers. Efficacy, minimal effective dose, and onset of action could certainly be determined before the drug has been given to any hypertensive patient. It would be extremely surprising if any major change in these predicted values would have to be made after the drug reaches hypertensive patients. It is even unlikely that new converting-enzyme inhibitors with substantially greater efficacy will be discovered since the presently available drugs seem to block conversion almost completely. The main and almost sole reason for testing new drugs in a large number of patient is to evaluate safety and tolerance, since there is no substitute at present for this elaborate and rather unsatisfactory approach.

References


Does pharmacological profiling of a new drug in normotensive volunteers provide a useful
guideline to antihypertensive therapy?
H R Brunner, B Waeber and J Nussberger

Hypertension. 1983;5:III101
doi: 10.1161/01.HYP.5.5_Pt_2.III101

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1983 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://hyper.ahajournals.org/content/5/5_Pt_2/III101

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/